ClinicalTrials.gg
CompletedNCT03985293Updated Jun 30, 2022Results posted

A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

A Phase 2 interventional study of Placebo and PF-06882961 in Diabetes Mellitus, Type 2, sponsored by Pfizer. Completed at 83 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-30.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 80 studies in Diabetes Mellitus, Type 2 by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 2 · Pfizer.

Enrollment
7th of 79
412 · median 50
Started
2019
with 1 other
Phase 2
18 of 80
none open now
Registered
69th of 80
by date

Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 7th largest by enrollment of the 79 interventional ones that give a count, is one of 2 that started in 2019, is one of 18 in phase 2, and was the 69th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 80 studies in Diabetes Mellitus, Type 2 by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Diabetes Mellitus, Type 2 by Pfizer, or all of them as a file.
02

Study summary

This multicenter, randomized, double-blind, placebo controlled, parallel group study is being conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of multiple dose levels of PF-06882961 in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise. In addition, the study is intended to enable selection of efficacious doses for future clinical development of PF-06882961.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with T2DM who are treated with metformin and/or diet and exercise
  • greater than or equal to 7% and less than or equal to 10.5%
  • Total body weight >50 kg (110 lb) with 24.5 to 45.4 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption
  • Diagnosis of Type 1 diabetes
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or within 6 months of screening
  • Any not considered cured
  • Personal or family history of MTC or MEN2, or participants with suspected MTC
  • Acute pancreatitis or history of chronic pancreatitis
  • Symptomatic gallbladder disease
  • Known medical history of active proliferative retinopathy and/or macular edema
  • Known medical history of active liver disease, including chronic active or C, or primary biliary cirrhosis
  • Known history of
  • Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)
  • abnormalities
  • Positive urine drug test
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
412 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    PF-06882961 2.5 milligrams (mg)

    Drug: PF-06882961

  • Experimental
    PF-06882961 10 mg

    Drug: PF-06882961

  • Experimental
    PF-06882961 40 mg

    Participants will be titrated up to 2 weeks to reach desired dose level

    Drug: PF-06882961

  • Experimental
    PF-06882961 80 mg

    Participants will be titrated up to 4 weeks to reach desired dose level

    Drug: PF-06882961

  • Experimental
    PF-06882961 120 mg

    Participants will be titrated up to 6 weeks to reach desired dose level

    Drug: PF-06882961

Interventions

  • DrugPlacebo

    4 matching placebo tablets taken twice a day (BID)

  • Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16

    HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels

    HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

    Time frame: Baseline, Week 16

  2. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2

    HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

    Time frame: Baseline, Week 2

  3. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4

    HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

    Time frame: Baseline, Week 4

  4. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6

    HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

    Time frame: Baseline, Week 6

  5. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8

    HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

    Time frame: Baseline, Week 8

  6. Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12

    HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

    Time frame: Baseline, Week 12

  7. Change From Baseline in Fasting Plasma Glucose at Week 2

    The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 milligram per deciliter (mg/dL) to 99 mg/dL.

    Time frame: Baseline, Week 2

  8. Change From Baseline in Fasting Plasma Glucose at Week 4

    The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

    Time frame: Baseline, Week 4

  9. Change From Baseline in Fasting Plasma Glucose at Week 6

    The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

    Time frame: Baseline, Week 6

  10. Change From Baseline in Fasting Plasma Glucose at Week 8

    The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

    Time frame: Baseline, Week 8

  11. Change From Baseline in Fasting Plasma Glucose at Week 12

    The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

    Time frame: Baseline, Week 12

  12. Change From Baseline in Fasting Plasma Glucose at Week 16

    The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

    Time frame: Baseline, Week 16

  13. Change From Baseline in Body Weight at Week 2

    Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 2

  14. Change From Baseline in Body Weight at Week 4

    Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 4

  15. Change From Baseline in Body Weight at Week 6

    Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 6

  16. Change From Baseline in Body Weight at Week 8

    Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 8

  17. Change From Baseline in Body Weight at Week 12

    Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 12

  18. Change From Baseline in Body Weight at Week 16

    Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 16

  19. Number of Participants With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs])

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.

    Time frame: Baseline up to Week 21

  20. Number of Participants With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality

    Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, PT/INR, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin); lipid panel (low density lipoprotein cholesterol, high density lipoprotein cholesterol).

    Time frame: Baseline Through Week 21

  21. Number of Participants With Treatment Emergent Vital Signs Abnormalities

    Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (\>=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>= 20 mmHg.

    Time frame: Baseline through Week 21

  22. Number of Participants With Treatment Emergent ECG Abnormalities

    ECG categorical abnormality criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (\>=) 300 millisecond (msec), b) \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) \>=140 msec, b) \>=50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and \<=480 msec, b) \>480 msec and \<=500 msec, c) \>500 msec, d) \>30 msec and \<=60 msec increase from baseline, e) \>60 msec increase from baseline.

    Time frame: Baseline Through Week 21

07

Results

Posted Jun 30, 2022

Participant flow

DOUBLE-BLIND TREATMENT
Participant flow — DOUBLE-BLIND TREATMENT
MilestonePlaceboPF-06882961 2.5mg BIDPF-06882961 10mg BIDPF-06882961 40mg BIDPF-06882961 80mg BIDPF-06882961 120mg BID
Started666868716771
Completed575463574738
Not completed9145142033
Withdrew: Adverse event52381524
Withdrew: Lost to follow-up130331
Withdrew: No longer meets eligibility criteria110100
Withdrew: Other120210
Withdrew: Protocol violation120001
Withdrew: Withdrawal by subject042017
FOLLOW-UP
Participant flow — FOLLOW-UP
MilestonePlaceboPF-06882961 2.5mg BIDPF-06882961 10mg BIDPF-06882961 40mg BIDPF-06882961 80mg BIDPF-06882961 120mg BID
Started575463574738
Completed575462574738
Not completed001000
Withdrew: Lost to follow-up001000

Outcome measures

PrimaryChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 16

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percent
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16
PercentPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16-0.02 (-0.22 to 0.19)-0.49 (-0.70 to -0.28)-0.91 (-1.11 to -0.72)-1.03 (-1.23 to -0.83)-0.96 (-1.18 to -0.74)-1.18 (-1.41 to -0.95)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.0071 · Difference in ls mean: -0.47 · 90% CI -0.76 to -0.18PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.90 · 90% CI -1.18 to -0.62PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -1.01 · 90% CI -1.30 to -0.73PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.94 · 90% CI -1.24 to -0.65PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -1.16 · 90% CI -1.47 to -0.86PF-06882961 = Test Placebo = Reference
SecondaryPercentage of Participants Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels
Percentage of ParticipantsPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Percentage of Participants Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels7.730.854.158.265.260.5
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Regression, Logistic · Odds ratio (or): 5.11 · 90% CI 1.84 to 14.18The Odds ratio model included multiple imputation. PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Regression, Logistic · Odds ratio (or): 16.85 · 90% CI 6.18 to 45.93The Odds ratio model included multiple imputation. PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Regression, Logistic · Odds ratio (or): 18.79 · 90% CI 7.03 to 50.21The Odds ratio model included multiple imputation. PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Regression, Logistic · Odds ratio (or): 23.97 · 90% CI 8.66 to 66.39The Odds ratio model included multiple imputation. PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Regression, Logistic · Odds ratio (or): 24.46 · 90% CI 8.72 to 68.57The Odds ratio model included multiple imputation. PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 2

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame:
Baseline, Week 2
Reported as:
Least squares mean · Percent
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2
PercentPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2-0.09 (-0.17 to -0.01)-0.18 (-0.26 to -0.09)-0.31 (-0.39 to -0.23)-0.29 (-0.37 to -0.21)-0.33 (-0.41 to -0.24)-0.35 (-0.43 to -0.28)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.1578 · Difference in ls mean: -0.09 · 90% CI -0.19 to 0.01PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.0003 · Difference in ls mean: -0.22 · 90% CI -0.32 to -0.12PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = 0.0013 · Difference in ls mean: -0.20 · 90% CI -0.30 to -0.10PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = 0.0001 · Difference in ls mean: -0.24 · 90% CI -0.34 to -0.14PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.26 · 90% CI -0.36 to -0.16PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 4

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · Percent
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4
PercentPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4-0.08 (-0.19 to 0.04)-0.38 (-0.50 to -0.26)-0.51 (-0.62 to -0.39)-0.63 (-0.74 to -0.52)-0.58 (-0.70 to -0.46)-0.64 (-0.75 to -0.53)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.0013 · Difference in ls mean: -0.30 · 90% CI -0.46 to -0.15PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.43 · 90% CI -0.58 to -0.28PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.55 · 90% CI -0.70 to -0.40PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.50 · 90% CI -0.66 to -0.35PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.56 · 90% CI -0.71 to -0.41PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 6

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Percent
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6
PercentPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6-0.07 (-0.21 to 0.07)-0.47 (-0.61 to -0.34)-0.71 (-0.84 to -0.57)-0.84 (-0.97 to -0.71)-0.79 (-0.93 to -0.65)-0.84 (-0.98 to -0.71)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.0004 · Difference in ls mean: -0.40 · 90% CI -0.59 to -0.22PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.64 · 90% CI -0.81 to -0.46PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.77 · 90% CI -0.95 to -0.59PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.72 · 90% CI -0.91 to -0.53PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.77 · 90% CI -0.95 to -0.59PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 8

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · Percent
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8
PercentPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8-0.13 (-0.29 to 0.03)-0.50 (-0.66 to -0.34)-0.78 (-0.93 to -0.62)-0.97 (-1.13 to -0.82)-0.92 (-1.09 to -0.76)-1.02 (-1.18 to -0.86)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.0054 · Difference in ls mean: -0.37 · 90% CI -0.59 to -0.15PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.65 · 90% CI -0.86 to -0.44PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.84 · 90% CI -1.06 to -0.63PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.80 · 90% CI -1.02 to -0.57PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.89 · 90% CI -1.11 to -0.67PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 12

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Percent
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12
PercentPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12-0.09 (-0.28 to 0.10)-0.53 (-0.72 to -0.34)-0.88 (-1.06 to -0.70)-1.06 (-1.25 to -0.88)-0.91 (-1.12 to -0.71)-1.11 (-1.32 to -0.91)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.0061 · Difference in ls mean: -0.44 · 90% CI -0.71 to -0.18PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.79 · 90% CI -1.05 to -0.54PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.98 · 90% CI -1.24 to -0.72PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -0.83 · 90% CI -1.10 to -0.56PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -1.03 · 90% CI -1.30 to -0.75PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 2

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 milligram per deciliter (mg/dL) to 99 mg/dL.

Time frame:
Baseline, Week 2
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 2
mg/dLPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Fasting Plasma Glucose at Week 2-5.58 (-12.66 to 1.49)-22.72 (-29.78 to -15.65)-21.96 (-28.91 to -15.01)-27.79 (-34.60 to -20.98)-24.18 (-31.28 to -17.08)-30.92 (-37.66 to -24.17)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.0014 · Difference in ls mean: -17.13 · 90% CI -25.94 to -8.33PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.0021 · Difference in ls mean: -16.38 · 90% CI -25.08 to -7.67Difference in LS Mean
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -22.20 · 90% CI -30.88 to -13.53PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = 0.0006 · Difference in ls mean: -18.59 · 90% CI -27.43 to -9.76PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -25.33 · 90% CI -34.00 to -16.67PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 4

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 4
mg/dLPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Fasting Plasma Glucose at Week 4-5.98 (-13.62 to 1.66)-17.77 (-25.46 to -10.09)-24.66 (-31.98 to -17.35)-33.42 (-40.83 to -26.00)-33.34 (-41.25 to -25.44)-34.06 (-41.52 to -26.60)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.0468 · Difference in ls mean: -11.79 · 90% CI -21.55 to -2.04PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.0012 · Difference in ls mean: -18.68 · 90% CI -28.12 to -9.25PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -27.44 · 90% CI -37.03 to -17.85PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -27.36 · 90% CI -37.22 to -17.51PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -28.09 · 90% CI -37.72 to -18.45PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 6

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 6
mg/dLPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Fasting Plasma Glucose at Week 6-0.88 (-8.62 to 6.86)-16.78 (-24.67 to -8.89)-26.41 (-33.88 to -18.94)-30.89 (-38.47 to -23.30)-28.36 (-36.51 to -20.21)-32.65 (-40.44 to -24.87)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.0091 · Difference in ls mean: -15.90 · 90% CI -25.90 to -5.90PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -25.53 · 90% CI -35.18 to -15.89PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -30.01 · 90% CI -39.80 to -20.21PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -27.48 · 90% CI -37.63 to -17.33PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -31.77 · 90% CI -41.77 to -21.78PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 8

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 8
mg/dLPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Fasting Plasma Glucose at Week 8-9.10 (-16.80 to -1.41)-12.73 (-20.53 to -4.93)-26.23 (-33.57 to -18.89)-29.74 (-37.26 to -22.23)-33.22 (-41.36 to -25.09)-34.31 (-42.46 to -26.16)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.5449 · Difference in ls mean: -3.63 · 90% CI -13.51 to 6.25PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.0031 · Difference in ls mean: -17.12 · 90% CI -26.62 to -7.63PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = 0.0005 · Difference in ls mean: -20.64 · 90% CI -30.31 to -10.96PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -24.12 · 90% CI -34.20 to -14.04PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -25.21 · 90% CI -35.44 to -14.97PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 12

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 12
mg/dLPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Fasting Plasma Glucose at Week 121.21 (-7.93 to 10.35)-6.49 (-15.70 to 2.73)-22.56 (-31.17 to -13.95)-32.01 (-40.89 to -23.14)-30.45 (-40.26 to -20.64)-32.38 (-42.83 to -21.94)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.2940 · Difference in ls mean: -7.70 · 90% CI -19.78 to 4.38PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.0008 · Difference in ls mean: -23.77 · 90% CI -35.37 to -12.17PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -33.23 · 90% CI -45.05 to -21.40PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -31.66 · 90% CI -44.14 to -19.19PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -33.59 · 90% CI -46.67 to -20.51PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 16

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 16
mg/dLPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Fasting Plasma Glucose at Week 161.31 (-7.58 to 10.20)-12.81 (-21.71 to -3.91)-24.53 (-32.88 to -16.18)-30.47 (-39.06 to -21.87)-25.71 (-35.15 to -16.26)-31.93 (-41.73 to -22.13)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.0464 · Difference in ls mean: -14.12 · 90% CI -25.77 to -2.47PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.0002 · Difference in ls mean: -25.84 · 90% CI -37.05 to -14.62PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -31.78 · 90% CI -43.20 to -20.35PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = 0.0002 · Difference in ls mean: -27.02 · 90% CI -39.03 to -15.01PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -33.24 · 90% CI -45.63 to -20.84PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Body Weight at Week 2

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame:
Baseline, Week 2
Reported as:
Least squares mean · Kilogram
Change From Baseline in Body Weight at Week 2
KilogramPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Body Weight at Week 2-0.15 (-0.47 to 0.17)-0.09 (-0.41 to 0.23)-0.12 (-0.44 to 0.19)-0.23 (-0.54 to 0.08)-0.57 (-0.89 to -0.24)-0.54 (-0.85 to -0.24)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.8011 · Difference in ls mean: 0.06 · 90% CI -0.33 to 0.44PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.9149 · Difference in ls mean: 0.02 · 90% CI -0.35 to 0.40PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = 0.7216 · Difference in ls mean: -0.08 · 90% CI -0.46 to 0.30PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = 0.0758 · Difference in ls mean: -0.42 · 90% CI -0.80 to -0.03PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = 0.0860 · Difference in ls mean: -0.40 · 90% CI -0.77 to -0.02PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Body Weight at Week 4

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · Kilogram
Change From Baseline in Body Weight at Week 4
KilogramPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Body Weight at Week 4-0.25 (-0.64 to 0.15)-0.33 (-0.72 to 0.07)-0.08 (-0.46 to 0.30)-0.77 (-1.15 to -0.39)-1.05 (-1.45 to -0.64)-1.33 (-1.71 to -0.95)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.7898 · Difference in ls mean: -0.08 · 90% CI -0.59 to 0.42PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.5829 · Difference in ls mean: 0.16 · 90% CI -0.33 to 0.66PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = 0.0827 · Difference in ls mean: -0.52 · 90% CI -1.02 to -0.03PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = 0.0101 · Difference in ls mean: -0.80 · 90% CI -1.31 to -0.29PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = 0.0004 · Difference in ls mean: -1.09 · 90% CI -1.59 to -0.59PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Body Weight at Week 6

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Kilogram
Change From Baseline in Body Weight at Week 6
KilogramPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Body Weight at Week 6-0.09 (-0.57 to 0.40)-0.19 (-0.68 to 0.31)-0.32 (-0.78 to 0.15)-0.83 (-1.31 to -0.36)-1.69 (-2.20 to -1.19)-2.34 (-2.83 to -1.85)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.7985 · Difference in ls mean: -0.10 · 90% CI -0.75 to 0.55PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.5484 · Difference in ls mean: -0.23 · 90% CI -0.86 to 0.40PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = 0.0541 · Difference in ls mean: -0.75 · 90% CI -1.38 to -0.11PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -1.60 · 90% CI -2.26 to -0.95PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -2.25 · 90% CI -2.90 to -1.60PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Body Weight at Week 8

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · Kilogram
Change From Baseline in Body Weight at Week 8
KilogramPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Body Weight at Week 8-0.36 (-0.89 to 0.16)-0.05 (-0.59 to 0.49)-0.27 (-0.78 to 0.23)-1.09 (-1.60 to -0.57)-1.97 (-2.52 to -1.42)-3.31 (-3.85 to -2.77)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.4692 · Difference in ls mean: 0.31 · 90% CI -0.40 to 1.03PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.8274 · Difference in ls mean: 0.09 · 90% CI -0.60 to 0.78PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = 0.0887 · Difference in ls mean: -0.72 · 90% CI -1.42 to -0.02PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = 0.0003 · Difference in ls mean: -1.61 · 90% CI -2.33 to -0.88PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -2.95 · 90% CI -3.67 to -2.22PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Body Weight at Week 12

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Kilogram
Change From Baseline in Body Weight at Week 12
KilogramPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Body Weight at Week 12-0.24 (-0.85 to 0.38)-0.09 (-0.72 to 0.53)-0.00 (-0.59 to 0.58)-1.05 (-1.65 to -0.44)-2.52 (-3.17 to -1.87)-3.81 (-4.46 to -3.16)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.7758 · Difference in ls mean: 0.15 · 90% CI -0.70 to 0.99PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.6367 · Difference in ls mean: 0.23 · 90% CI -0.58 to 1.05PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = 0.1082 · Difference in ls mean: -0.81 · 90% CI -1.63 to 0.02PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -2.28 · 90% CI -3.14 to -1.42PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -3.57 · 90% CI -4.44 to -2.70PF-06882961 = Test Placebo = Reference
SecondaryChange From Baseline in Body Weight at Week 16

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Kilogram
Change From Baseline in Body Weight at Week 16
KilogramPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Change From Baseline in Body Weight at Week 16-0.43 (-1.12 to 0.25)0.02 (-0.68 to 0.72)-0.06 (-0.71 to 0.60)-1.16 (-1.84 to -0.49)-2.48 (-3.20 to -1.75)-4.60 (-5.34 to -3.86)
Statistical analysis
  • Placebo vs PF-06882961 2.5 BID · Mixed Models Analysis · p = 0.4325 · Difference in ls mean: 0.45 · 90% CI -0.50 to 1.41PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 10 mg BID · Mixed Models Analysis · p = 0.4978 · Difference in ls mean: 0.38 · 90% CI -0.54 to 1.30PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 40 mg BID · Mixed Models Analysis · p = 0.1970 · Difference in ls mean: -0.73 · 90% CI -1.66 to 0.20PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 80 mg BID · Mixed Models Analysis · p = 0.0006 · Difference in ls mean: -2.04 · 90% CI -3.01 to -1.07PF-06882961 = Test Placebo = Reference
  • Placebo vs PF-06882961 120 mg BID · Mixed Models Analysis · p = <.0001 · Difference in ls mean: -4.17 · 90% CI -5.15 to -3.18PF-06882961 = Test Placebo = Reference
SecondaryNumber of Participants With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs])

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.

Time frame:
Baseline up to Week 21
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs])
ParticipantsPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Number of Participants With Treatment Emergent AEs323231424344
Number of Participants With Treatment Emergent SAEs112621
SecondaryNumber of Participants With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, PT/INR, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin); lipid panel (low density lipoprotein cholesterol, high density lipoprotein cholesterol).

Time frame:
Baseline Through Week 21
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality
ParticipantsPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Number of Participants With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality605757576064
SecondaryNumber of Participants With Treatment Emergent Vital Signs Abnormalities

Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (\>=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>= 20 mmHg.

Time frame:
Baseline through Week 21
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Vital Signs Abnormalities
ParticipantsPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
Supine SBP <90 mmHg000000
Supine SBP increase >=30 mmHg343305
Supine SBP decrease >=30 mmHg443550
Supine DBP <50 mmHg100101
Supine DBP increase >=20 mmHg112333
Supine DBP decrease >=20 mmHg341321
Supine pulse rate <40 bpm000000
Supine pulse rate >120 bpm000000
SecondaryNumber of Participants With Treatment Emergent ECG Abnormalities

ECG categorical abnormality criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (\>=) 300 millisecond (msec), b) \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) \>=140 msec, b) \>=50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and \<=480 msec, b) \>480 msec and \<=500 msec, c) \>500 msec, d) \>30 msec and \<=60 msec increase from baseline, e) \>60 msec increase from baseline.

Time frame:
Baseline Through Week 21
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent ECG Abnormalities
ParticipantsPlaceboPF-06882961 2.5 BIDPF-06882961 10 mg BIDPF-06882961 40 mg BIDPF-06882961 80 mg BIDPF-06882961 120 mg BID
PR interval ≥300 msec000001
%Change in PR interval ≥25/50%300010
QRS interval ≥140 msec110000
%Change in QRS interval ≥50%110000
QTcF interval >450 and ≤480 msec232134
QTcF interval >480 and ≤500 msec000001
QTcF interval >500 msec000000
Change in QTcF interval >30 and ≤60 msec232636
Change in QTcF interval >60 msec001103

Adverse events

Collected over Baseline up to Week 21. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/66 (0%)1/66 (1.5%)15/66 (22.7%)
PF-06882961 2.5mg BID1/68 (1.5%)1/68 (1.5%)21/68 (30.9%)
PF-06882961 10mg BID0/68 (0%)2/68 (2.9%)17/68 (25%)
PF-06882961 40mg BID2/71 (2.8%)6/71 (8.5%)33/71 (46.5%)
PF-06882961 80mg BID0/67 (0%)2/67 (3%)40/67 (59.7%)
PF-06882961 120mg BID0/71 (0%)1/71 (1.4%)35/71 (49.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlaceboPF-06882961 2.5mg BIDPF-06882961 10mg BIDPF-06882961 40mg BIDPF-06882961 80mg BIDPF-06882961 120mg BID
Ankle fractureInjury, poisoning and procedural complications1/660/680/680/710/670/71
Cholecystitis acuteHepatobiliary disorders0/660/680/680/711/670/71
HypertensionVascular disorders0/660/680/680/711/670/71
AnaemiaBlood and lymphatic system disorders0/660/681/680/710/670/71
Acute myocardial infarctionCardiac disorders0/661/680/680/710/670/71
COVID-19 pneumoniaInfections and infestations0/661/680/681/710/670/71
Multiple sclerosisNervous system disorders0/660/681/680/710/670/71
PalpitationsCardiac disorders0/660/680/681/710/670/71
Drug-induced liver injuryHepatobiliary disorders0/660/680/681/710/670/71
PneumoniaInfections and infestations0/660/680/681/710/670/71
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboPF-06882961 2.5mg BIDPF-06882961 10mg BIDPF-06882961 40mg BIDPF-06882961 80mg BIDPF-06882961 120mg BID
NauseaGastrointestinal disorders2/665/685/6811/7122/6723/71
VomitingGastrointestinal disorders0/660/681/685/7111/6718/71
DiarrhoeaGastrointestinal disorders2/663/684/688/7112/677/71
DyspepsiaGastrointestinal disorders0/664/683/682/719/672/71
HeadacheNervous system disorders4/664/681/685/712/677/71
HyperglycaemiaMetabolism and nutrition disorders6/662/681/680/714/670/71
HypoglycaemiaMetabolism and nutrition disorders0/661/681/684/716/673/71
Gastrooesophageal reflux diseaseGastrointestinal disorders0/661/682/682/714/675/71
Urinary tract infectionInfections and infestations0/661/680/685/713/671/71
Decreased appetiteMetabolism and nutrition disorders0/662/680/682/711/675/71

Baseline characteristics

A total of 412 participants were assigned to treatment, 411 of whom were treated; 1 participant randomized to the PF-06882961 120 mg BID group was not treated.

Age, Continuous
Age, Continuous(Years)PlaceboPF-06882961 2.5mg BIDPF-06882961 10mg BIDPF-06882961 40mg BIDPF-06882961 80mg BIDPF-06882961 120mg BIDTotal
Mean (SD)57.9 ± 10.2758.9 ± 9.3058.1 ± 9.4359.6 ± 8.5858.4 ± 9.1858.8 ± 9.4358.6 ± 9.33
Age, Customized
Age, Customized(Participants)PlaceboPF-06882961 2.5mg BIDPF-06882961 10mg BIDPF-06882961 40mg BIDPF-06882961 80mg BIDPF-06882961 120mg BIDTotal
18-44 Years64725832
45-64 Years444341454244259
>=65 Years162120242019120
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPF-06882961 2.5mg BIDPF-06882961 10mg BIDPF-06882961 40mg BIDPF-06882961 80mg BIDPF-06882961 120mg BIDTotal
Female333033373237202
Male333835343534209
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPF-06882961 2.5mg BIDPF-06882961 10mg BIDPF-06882961 40mg BIDPF-06882961 80mg BIDPF-06882961 120mg BIDTotal
Hispanic or Latino242217242318128
Not Hispanic or Latino424650474452281
Unknown or Not Reported0010012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPF-06882961 2.5mg BIDPF-06882961 10mg BIDPF-06882961 40mg BIDPF-06882961 80mg BIDPF-06882961 120mg BIDTotal
White575753585959343
Black or African American241061427
Asian57466735
Native Hawaiian or Other Pacific Islander1000012
Not reported1011104
Age Range
Age Range(Years)PlaceboPF-06882961 2.5mg BIDPF-06882961 10mg BIDPF-06882961 40mg BIDPF-06882961 80mg BIDPF-06882961 120mg BIDTotal
Median59.0 (28 to 76)59.0 (38 to 74)60.0 (38 to 75)61.0 (31 to 75)58.0 (35 to 75)60.0 (40 to 74)59.0 (28 to 76)
08

Study locations

83 sites
  • Holy Trinity Medical Clinic
    Harbor City, California 90710, United States
  • Innovative Clinical Research, Inc.
    Harbor City, California 90710, United States
  • Long Beach Clinical Trials Services, Inc.
    Long Beach, California 90806, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Empire Clinical Research
    Pomona, California 91767, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California 91730, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • University Clinical Investigators, Incorporated
    Tustin, California 92780, United States
  • San Fernando Valley Health Institute, LLC
    Van Nuys, California 91405, United States
  • Diablo Clinical Research Incorporated
    Walnut Creek, California 94598, United States
  • Accel Research Sites - DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32204, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32216, United States
  • NewPhase Clinical Trials, Corp.
    Miami Beach, Florida 33140, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Sunshine Research Center, Inc
    Opa-locka, Florida 33054, United States
  • Andres Patron D.O. P.A.
    Pembroke Pines, Florida 33026, United States
  • Ellipsis Group
    Alpharetta, Georgia 30022, United States
  • East Coast Institute for Research, LLC
    Macon, Georgia 31210, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Buynak Clinical Research
    Valparaiso, Indiana 46383, United States
  • Viable Research Management LLC
    Henderson, Nevada 89014, United States
  • Premier Research
    Trenton, New Jersey 08611, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Velocity Clinical Research
    Cincinnati, Ohio 45242, United States
  • Conrad Clinical Research
    Edmond, Oklahoma 73013, United States
  • Family Medical Associates
    Levittown, Pennsylvania 19056, United States
  • Preferred Primary Care Physicians, Inc.
    Pittsburgh, Pennsylvania 15236, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Palmetto Primary Care Physicians (physicals only)
    Summerville, South Carolina 29485, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Endocrine Associates
    Houston, Texas 77004, United States
  • PrimeCare Medical Group
    Houston, Texas 77024, United States
  • Juno Research, LLC
    Houston, Texas 77074, United States
  • Northeast Clinical Research of San Antonio
    Live Oak, Texas 78233, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Martin Diagnostic Clinic
    Tomball, Texas 77375, United States
  • Rainier Clinical Research Center, Inc.
    Renton, Washington 98057, United States
  • MHAT Dobrich AD
    Dobrich, 9300, Bulgaria
  • Medical Center ASKLEPII OOD
    Dupnitsa, 2600, Bulgaria
  • UMHAT Pulmed
    Plovdiv, 4002, Bulgaria
  • Fourth MHAT - Sofia EAD
    Sofia, 1606, Bulgaria
  • MHAT "Doverie" AD
    Sofia, 1632, Bulgaria
  • MC "New rehabilitation center" EOOD
    Stara Zagora, 6000, Bulgaria
  • GA Research Associates Ltd.
    Moncton, New Brunswick E1G 1A7, Canada
  • Aggarwal and Associates Limited
    Brampton, Ontario L6T 0G1, Canada
  • Manna Research (Toronto)
    Toronto, Ontario M9W4L6, Canada
  • Manna Research (Quebec)
    Levis, Quebec G6W 0M5, Canada
  • Manna Research (Mirabel)
    Mirabel, Quebec J7J 2K8, Canada
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Diex Recherche Victoriaville Inc.
    Victoriaville, Quebec G6P 6P6, Canada
  • Diex Recherche Quebec Inc.
    Quebec, G1N 4V3, Canada
  • Centre de Recherche Saint-Louis
    Quebec, G1W 4R4, Canada
  • Alpha Recherche Clinique
    Quebec, G3K2P8, Canada
  • Belinus Orvosi es Szamitastechnikai Bt
    Debrecen, 4025, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • CRU Hungary Kft.
    Miskolc, 3529, Hungary
  • Borbanya Praxis Egeszsegugyi KFT
    Nyiregyhaza, H-4405, Hungary
  • Clinfan Kft.
    Szekszard, H-7100, Hungary
  • Yonsei University-Wonju Severance Christian Hospital
    Wonju-si, Gangwon-do 26426, Korea, Republic of
  • Hanyang University Guri Hospital
    Guri-si, Gyeonggi-do 11923, Korea, Republic of
  • Ajou University Hospital
    Suwon-si, Gyeonggi-do 16499, Korea, Republic of
  • Samsung Medical Center
    Gangnam-Gu, Seoul 06351, Korea, Republic of
  • Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
    Bialystok, 15-351, Poland
  • Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne DIAB-ENDO-MET Sp. z o. o.
    Krakow, 31-261, Poland
  • Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer
    Lodz, 94-060, Poland
  • MEDICOME Sp. z o.o.
    Oswiecim, 32-600, Poland
  • KO-MED CENTRA KLINICZNE Sp. z o.o. Ośrodek Badań Klinicznych w Puławach
    Puławy, 24-100, Poland
  • Centralny Szpital Kliniczny MSWiA
    Warszawa, 02-507, Poland
  • Metabol KLINIK s.r.o.
    Bratislava, 811 08, Slovakia
  • Medispektrum, s.r.o
    Bratislava, 851 01, Slovakia
  • HUMAN-CARE, s.r.o.
    Kosice, 040 01, Slovakia
  • SchronerMED s.r.o.
    Moldava nad Bodvou, 04501, Slovakia
  • Funkystuff, s.r.o.
    Nove Zamky, 940 01, Slovakia
  • DIAB s.r.o.
    Roznava, 048 01, Slovakia
  • MUDr. Jana Rociakova, s.r.o.
    Zilina, 010 01, Slovakia
  • Far Eastern Memorial Hospital
    New Taipei City, 220, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jun 2021, 19 months.

Results were first posted in Jun 2022, 1 year after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 19 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2019
First posted
Jun 13, 2019
StartActual
Oct 15, 2019
Primary completionActual
Jun 8, 2021
CompletionActual
Jul 7, 2021
Results first posted
Jun 30, 2022
Last update
Jun 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03985293
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 13, 2019
Start date
Oct 15, 2019
Primary completion
Jun 8, 2021
Completion
Jul 7, 2021
Results posted
Jun 30, 2022
Last update
Jun 30, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danuglipron

Start the discussion